Adderall XR Complete Drug-Drug Interaction Profile

How Adderall XR Works: Mechanism Relevant to Interactions

Adderall XR releases amphetamine salts in two pulses: 50% immediate-release and 50% delayed-release beads, producing a therapeutic window of roughly 10 to 12 hours. Understanding its mechanism is necessary for predicting interactions, because most arise at the same molecular targets the drug uses therapeutically.

Monoamine Release and Reuptake Inhibition

Amphetamine enters presynaptic terminals via the dopamine transporter (DAT) and norepinephrine transporter (NET) [1]. Once inside, it reverses these transporters and displaces vesicular monoamine stores, flooding synapses with dopamine, norepinephrine, and, to a lesser extent, serotonin [1]. It also weakly inhibits monoamine oxidase (MAO), which is the direct basis for its most dangerous interaction class [2].

Renal Elimination and Urinary pH

Approximately 30 to 40% of an amphetamine dose is excreted unchanged in urine, and this fraction rises sharply in acidic urine and falls in alkaline urine [3]. At urinary pH 5, amphetamine half-life may be as short as 7 to 8 hours. At pH 8, it can extend beyond 20 hours, meaningfully raising peak plasma levels and duration of cardiovascular and CNS effects [3]. Any drug that shifts urinary pH therefore functions as a pharmacokinetic interaction partner.

CYP2D6 Metabolism

A smaller fraction of amphetamine undergoes hepatic oxidation via CYP2D6 to 4-hydroxyamphetamine [4]. Potent CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) slow this pathway, increasing amphetamine exposure. This interaction is pharmacokinetically modest in extensive metabolizers but more pronounced in patients who are already intermediate metabolizers genetically [4].

MAO Inhibitors: Absolute Contraindication

This is the only absolute contraindication in Adderall XR's interaction profile. Co-administration with any MAOI, or use within 14 days of stopping one, may cause a hypertensive crisis, hyperthermia, and death [2].

Mechanism of the MAOI Interaction

Amphetamine floods the synapse with monoamines while simultaneously inhibiting their reuptake. MAO normally degrades the excess. When MAO is blocked pharmacologically, dopamine and norepinephrine accumulate without a ceiling. Blood pressure can rise to levels associated with hypertensive encephalopathy or intracerebral hemorrhage within minutes [2].

Which MAOIs Are Covered

The contraindication covers all irreversible non-selective MAOIs (phenelzine, tranylcypromine, isocarboxazid), the irreversible MAO-B selective agent selegiline at any dose, and the reversible MAOI moclobemide where it is prescribed [5]. Linezolid and methylene blue carry weak MAOI activity and are also listed on the FDA Adderall label as requiring caution or avoidance [2].

Clinical Management

Stop any MAOI at least 14 days before starting Adderall XR. For selegiline transdermal (Emsam), the same 14-day washout applies. If a patient presents on both agents inadvertently, do not abruptly discontinue either without hemodynamic monitoring in an inpatient setting.

Serotonergic Agents: Serotonin Syndrome Risk

Amphetamine increases synaptic serotonin in addition to catecholamines [1]. Combining it with other serotonergic drugs produces additive serotonin excess. The Hunter Criteria define serotonin syndrome as the triad of clonus, hyperthermia, and agitation, and mild cases can escalate rapidly [6].

SSRIs and SNRIs

Fluoxetine and paroxetine are both CYP2D6 inhibitors and serotonin reuptake inhibitors, creating a dual interaction: they raise amphetamine plasma levels pharmacokinetically and add serotonergic load pharmacodynamically [4]. A 2021 pharmacovigilance analysis in the FDA Adverse Event Reporting System found that the combination of amphetamines with SSRIs was associated with a disproportionately higher reporting rate for serotonin syndrome compared with either agent alone [7].

Sertraline, escitalopram, and venlafaxine are weaker CYP2D6 inhibitors but still carry serotonergic additive risk. Patients on these combinations should be counseled on early warning signs: restlessness, diaphoresis, myoclonus, and rapid heart rate [6].

Tramadol

Tramadol inhibits serotonin and norepinephrine reuptake and is a mu-opioid agonist. Co-prescription with Adderall XR has been documented in case reports of serotonin syndrome, particularly at tramadol doses above 200 mg/day [8]. The combination should generally be avoided; if pain management requires it, prescribers should use the lowest tramadol dose and monitor for serotonergic signs.

Triptans and St. John's Wort

Sumatriptan and other triptans act as 5-HT1B/1D agonists. The theoretical risk of serotonin syndrome is low with triptans alone, but real-world case series suggest the risk increases when triptans are layered onto an already-elevated serotonergic background from stimulant use [9]. St. John's Wort (Hypericum perforatum) is a weak serotonin reuptake inhibitor and MAO inhibitor; patients should be explicitly asked about its use because it is sold over the counter [9].

Alkalinizing Agents: Pharmacokinetic Amplifiers

Any drug or supplement that raises urinary pH reduces renal clearance of amphetamine, extending its half-life and raising steady-state plasma concentrations [3].

Sodium Bicarbonate and Antacids

Sodium bicarbonate, when taken in doses used for heartburn (325 to 650 mg), raises urinary pH by 0.5 to 1.0 units within 1 to 2 hours [3]. A controlled crossover study showed that alkalinization of urine to pH 8 produced a mean 3-fold increase in amphetamine plasma AUC compared with acidified urine [3]. High-dose antacids containing calcium carbonate (Tums) or magnesium hydroxide (Milk of Magnesia) can produce a similar effect.

Patients should take Adderall XR at least 2 hours before or after antacid use, and those on sodium bicarbonate infusions in the hospital setting require reassessment of amphetamine dose.

Acetazolamide

Acetazolamide, a carbonic anhydrase inhibitor used for glaucoma and altitude sickness, alkalinizes urine substantially and is specifically named in the Adderall XR prescribing information as an agent that increases amphetamine blood levels [2]. Concurrent use requires close monitoring for signs of amphetamine toxicity (tachycardia, hypertension, insomnia, stereotypy).

Potassium Citrate and Citrate-Containing Supplements

Potassium citrate (used to prevent kidney stones) and citrate-containing supplements can raise urinary pH to 7 to 8 over weeks of use. This is a slow-onset interaction but equally relevant in patients on chronic urological regimens [3].

Acidifying Agents: Pharmacokinetic Reducers

The mirror image of the alkalinization problem occurs when urine pH drops. Acidifying agents accelerate amphetamine clearance, potentially causing breakthrough ADHD symptoms or narcolepsy [2].

Ascorbic Acid (Vitamin C)

Doses of ascorbic acid above 500 mg/day can acidify urine enough to detectably reduce amphetamine half-life [10]. Parents of children on Adderall XR frequently administer vitamin C supplements; they should be counseled to time these doses in the evening, after the therapeutic window has closed, rather than in the morning alongside the capsule [10].

Ammonium Chloride

Ammonium chloride, occasionally used in cough preparations or as a diuretic adjunct, is a direct urinary acidifier and is listed on the FDA label as decreasing amphetamine efficacy [2]. This combination should be avoided when possible.

Antihypertensives and Cardiovascular Drugs

Amphetamine increases heart rate and blood pressure by releasing norepinephrine onto cardiac and vascular adrenoceptors [1]. This opposes the effects of virtually every antihypertensive class.

Alpha Blockers and Beta Blockers

Alpha-1 blockers (doxazosin, prazosin) may paradoxically allow unopposed beta-mediated tachycardia when amphetamine-driven alpha stimulation is blocked. Non-selective beta blockers (propranolol, nadolol) block cardiac beta-1 effects but leave alpha-mediated vasoconstriction unopposed, potentially worsening hypertension [11].

A cardiology consensus statement from the American Heart Association notes that stimulant medications produce mean increases of approximately 2 to 4 mmHg systolic BP and 1 to 2 bpm heart rate at therapeutic doses, but the variance across individuals is substantial [11]. Patients with pre-existing hypertension should have BP checked within 2 to 4 weeks of initiating or dose-escalating Adderall XR.

Clonidine and Guanfacine

Clonidine (Kapvay) and guanfacine (Intuniv) are alpha-2 agonists sometimes co-prescribed with stimulants for ADHD. When Adderall XR is abruptly discontinued while a patient is on clonidine, rebound hypertension from clonidine withdrawal can unmask, because the stimulant had been partially offsetting the hypotensive load [12]. Tapered discontinuation of stimulants is advisable in this combination.

Digoxin

Amphetamine-driven increases in sympathetic tone may reduce the therapeutic effect of digoxin in rate control for atrial fibrillation [2]. Heart rate should be monitored more frequently in patients on this combination.

CYP2D6 Inhibitors: Elevated Amphetamine Exposure

Several commonly prescribed psychiatric and non-psychiatric drugs inhibit CYP2D6 substantially, raising amphetamine AUC and prolonging its effects.

Fluoxetine and Paroxetine

Both are potent, essentially irreversible CYP2D6 inhibitors. A pharmacokinetic study in healthy volunteers found that 20 mg/day fluoxetine increased d-amphetamine AUC by approximately 25 to 35% [4]. For a patient on Adderall XR 20 mg, this could translate to an effective exposure equivalent to 25 to 27 mg, enough to produce cardiovascular or sleep-disrupting effects in sensitive individuals [4].

Bupropion

Bupropion (Wellbutrin, Zyban) is both a CYP2D6 inhibitor and a norepinephrine-dopamine reuptake inhibitor. It adds catecholaminergic load pharmacodynamically while simultaneously elevating amphetamine plasma levels pharmacokinetically. Case reports document seizure threshold lowering with this combination, and bupropion's own pro-seizure risk is dose-dependent [13]. For patients who need bupropion for depression or smoking cessation alongside Adderall XR, clinicians should start with the lowest bupropion dose (150 mg SR) and avoid doses above 300 mg/day.

Quinidine

Quinidine is one of the most potent CYP2D6 inhibitors in clinical use. It is now rarely used as an antiarrhythmic but still prescribed as dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect. Patients on Nuedexta who are started on Adderall XR should be treated as CYP2D6 poor metabolizers for dosing purposes [4].

Proton Pump Inhibitors and H2 Blockers

This interaction is more nuanced than simple pH manipulation. PPIs (omeprazole, pantoprazole, esomeprazole) raise gastric pH, which can accelerate dissolution of the Adderall XR extended-release bead coat and alter the drug's absorption kinetics [2]. The effect is on gastric rather than urinary pH, affecting rate of absorption rather than elimination. Clinical significance is generally modest, but patients who report that Adderall XR "wears off faster" or "hits all at once" should be asked about concurrent PPI use.

Lithium

Lithium carries a dual interaction consideration. Animal data show that lithium may attenuate the anorectic and stimulant effects of amphetamine by modulating dopamine sensitization pathways [14]. In bipolar patients who receive Adderall XR for comorbid ADHD, lithium's mood-stabilizing properties may partially counteract the euphorigenic and mood-elevating profile of amphetamine. This is not always unwanted, but it does mean the ADHD-symptom response may be blunted, potentially leading prescribers to escalate the stimulant dose unnecessarily [14].

Opioids and CNS Depressants

Amphetamine and opioids are pharmacodynamically antagonistic in some respects: amphetamine blunts opioid-induced sedation and historically was used perioperatively for this purpose [2]. But the combination is clinically hazardous in a different way: stimulant-driven masking of opioid sedation may lead patients or providers to underestimate respiratory depression. The combination of amphetamine with high-dose opioids in pain management requires careful titration and naloxone co-prescription in outpatient settings, consistent with CDC opioid prescribing guidance [15].

Thyroid Hormones

Thyroid hormones sensitize the myocardium to catecholamines [16]. Patients on levothyroxine who are also prescribed Adderall XR may experience exaggerated tachycardia and palpitations. A baseline TSH and free T4 should be checked before initiating Adderall XR in patients on thyroid replacement, and a 12-lead ECG is reasonable in those with TSH <0.5 mIU/L, indicating relative hyperthyroidism [16].

Insulin and Oral Hypoglycemic Agents

Amphetamine suppresses appetite and accelerates glucose metabolism via catecholamine-mediated glycogenolysis [2]. In patients with type 1 or type 2 diabetes, this can cause unpredictable glycemic shifts. The American Diabetes Association 2024 Standards of Care recommend more frequent glucose self-monitoring when any stimulant is initiated in a patient on insulin or sulfonylureas [17]. Hypoglycemia unawareness is a particular concern, because amphetamine-driven autonomic arousal can mask early adrenergic warning signs of low blood glucose.

Anticoagulants: Indirect Considerations

No direct pharmacokinetic interaction between amphetamine and warfarin or direct oral anticoagulants (DOACs) has been established in primary pharmacokinetic studies. However, Adderall XR's appetite-suppressing effects can lead to significant reductions in dietary vitamin K intake over weeks, which may raise INR in warfarin patients [2]. INR should be rechecked 4 to 6 weeks after Adderall XR initiation in any patient on warfarin.

Pediatric-Specific Interaction Considerations

The MTA Cooperative Group study (N=579, published in Archives of General Psychiatry 1999) remains the landmark pediatric trial for stimulant efficacy in ADHD [18]. It did not systematically evaluate drug interactions, but its close follow-up protocol documented cardiovascular signals that inform current interaction monitoring thresholds. Children metabolize amphetamine somewhat faster than adults, meaning interaction effects that shift half-life may have proportionally larger clinical impact in pediatric patients [18].

Children are also more likely to receive vitamin C supplements, antibiotic courses (some of which affect urinary pH transiently), and OTC cold medications containing pseudoephedrine or phenylephrine. Each of these adds to the interaction burden and should be reviewed at every visit.

Practical Interaction Checklist for Prescribers

Reviewing the complete medication list before initiating Adderall XR takes under five minutes and prevents the majority of serious interactions. The following categories warrant explicit documentation and action:

• MAOI status. Confirm washout of at least 14 days for any MAOI, including linezolid and methylene blue.
• Serotonergic agents. Document dose and timing of any SSRI, SNRI, tramadol, or triptan.
• Urinary pH modifiers. Ask about antacid use, vitamin C supplementation, and potassium citrate.
• CYP2D6 inhibitors. Identify fluoxetine, paroxetine, bupropion, and quinidine-containing products.
• Cardiovascular drugs. Record current antihypertensives, digoxin, and any antiarrhythmics.
• Thyroid status. Obtain recent TSH; if <0.5 mIU/L, reconsider or monitor closely.
• Diabetes medications. Increase glucose monitoring frequency if the patient is on insulin or sulfonylureas.
• Anticoagulation. Recheck INR at 4 to 6 weeks if the patient is on warfarin.

The FDA prescribing information for Adderall XR is updated periodically and should be cross-referenced whenever a new interaction concern arises [2].